 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Kolon Life Sciences announced on the 11th that it has registered a patent for anti-cancer gene therapy KLS-3021-related 'recombinant Vaccinia virus and pharmaceutical composition including it' in Canada and Singapore.
Kolon Life Science has developed a recombinant bexenia virus technology that adds gene PH-20 and sPD1-Fc with the aim of increasing the effectiveness of treatment for Vaccinia virus-based tumor killing viruses that have increased the selection of cancer cells through gene editing.
The PH-20 gene is an enzyme that decomposes hyaluronic acid, a major component of non-cellular substrate that acts as a physical barrier to the delivery of therapeutic materials, and helps spread the tumor-killing virus and penetrate immune cells. The sPD1-Fc gene blocks the immune gate factor (PD-L1/2), one of the immune avoidance mechanisms of cancer cells, and maintains the activity of immune cells that remove cancer cells.
Furthermore, the patent also included a technology to additionally combine IL-12, a therapeutic gene that activates immune cells that attack cancer cells such as T cells and NK cells.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
